BioCryst Pharmaceuticals, Inc. (BCRX)

BioCryst Pharmaceuticals, Inc. (BCRX) Healthcare & Pipeline Overview

BioCryst Pharmaceuticals, Inc. is a biotechnology firm specializing in novel, oral, small-molecule therapies for rare diseases and acute conditions. The company leverages its research and development capabilities to advance a pipeline of candidates, including ORLADEYO for hereditary angioedema, alongside strategic collaborations to address significant unmet medical needs.

What Is the Investment Thesis for BCRX?

BioCryst Pharmaceuticals, Inc. presents an investment thesis centered on its commercial product ORLADEYO and a pipeline targeting rare and complement-mediated diseases. ORLADEYO, an oral therapy for hereditary angioedema, is a key value driver, offering a differentiated profile in a market with unmet needs. Continued global expansion and increased patient adoption of ORLADEYO are critical growth catalysts. The company's pipeline, particularly BCX9930 in Phase II for complement-mediated diseases, represents significant future potential, addressing a broad range of conditions. Successful progression of BCX9930 and other early-stage assets like BCX9250 and Galidesivir through clinical trials could unlock substantial value. Strategic collaborations further de-risk development and expand market reach. Financially, the company operates with a market capitalization of $2.11B. While currently unprofitable with a profit margin of -51.7% and a gross margin of 18.9%, typical for a biotech in growth phase, successful commercialization of pipeline assets and ORLADEYO's continued growth are essential for achieving profitability. The company's beta of 0.57 suggests lower volatility compared to the broader market, which may appeal to certain investor profiles.

Based on FMP financials and quantitative analysis

BCRX Key Highlights

• Market Capitalization: BioCryst Pharmaceuticals maintains a market capitalization of $2.11B, reflecting its valuation as a commercial-stage biotechnology company with a developing pipeline.
• Profitability Metrics: The company reported a profit margin of -51.7%, indicating it is currently operating at a loss, which is common for biotechnology firms investing heavily in research and development.
• Gross Margin Performance: BioCryst's gross margin stands at 18.9%, suggesting the cost of goods sold for its marketed products consumes a significant portion of revenue.
• Market Volatility: With a Beta of 0.57, BioCryst Pharmaceuticals exhibits lower volatility compared to the overall market, potentially indicating a more stable stock performance relative to broader market movements.
• Dividend Policy: The company does not currently offer a dividend yield, aligning with the typical strategy of growth-oriented biotechnology companies that reinvest earnings into R&D and pipeline expansion.

Who Are BCRX's Competitors?

BCRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BCRX's Key Strengths?

• Commercialized products, including ORLADEYO for hereditary angioedema, providing current revenue streams.
• Diverse and innovative pipeline of oral small-molecule candidates targeting significant unmet medical needs.
• Strong network of strategic collaborations and in-license relationships for global reach and shared development.
• Expertise in developing oral therapies, offering potential patient convenience advantages over injectables.

What Are BCRX's Weaknesses?

• Currently unprofitable, with a significant negative profit margin of -51.7%, indicating high R&D and operational costs.
• Reliance on the commercial success of a limited number of approved products, primarily ORLADEYO.
• Early-stage nature of several key pipeline assets (Phase I/II), implying long development timelines and inherent risks.
• Relatively low gross margin of 18.9%, suggesting challenges in cost efficiency or pricing power.

What Could Drive BCRX Stock Higher?

• Announcement of Phase II clinical trial results for BCX9930 in complement-mediated diseases, which could significantly de-risk the program and provide clarity on its therapeutic potential.
• Progression of BCX9250 from Phase I to Phase II clinical trials for fibrodysplasia ossificans progressiva, indicating positive initial safety and pharmacokinetic data.
• Continued global market expansion and increased patient adoption rates for ORLADEYO, driving sustained revenue growth and market share in the hereditary angioedema market.
• Initiation of further clinical development stages or new trials for Galidesivir, particularly if global health events highlight the need for broad-spectrum antiviral treatments.

What Are the Key Risks for BCRX?

• Financial-distress signal — its Altman Z-Score of -5.82 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for pipeline assets like BCX9930, BCX9250, or Galidesivir, which could lead to significant R&D write-offs and impact future revenue potential.
• Intense competition in the hereditary angioedema market and other therapeutic areas, potentially limiting ORLADEYO's market share or pricing power.
• Regulatory delays or rejections for new drug applications, hindering the commercialization of pipeline candidates and extending time to market.
• Challenges in achieving sustained profitability, as indicated by the current negative profit margin of -51.7%, requiring continued high investment in R&D and commercialization.
• Adverse events or safety concerns emerging from ongoing clinical trials or post-market surveillance, which could impact product viability or regulatory standing.

What Are the Growth Opportunities for BCRX?

• Expansion of ORLADEYO Market Penetration: ORLADEYO, an oral prophylactic treatment for hereditary angioedema (HAE), represents a significant growth driver. The global HAE market is substantial, with a continuous need for effective and convenient treatment options. BioCryst has an opportunity to expand ORLADEYO's market share by increasing patient adoption in existing territories and securing additional regulatory approvals and commercial launches in new international markets through its established collaborations. The convenience of an oral therapy versus traditional injectables provides a competitive advantage, potentially leading to increased prescription rates and sustained revenue growth over the next 3-5 years as awareness and physician comfort grow.
• Advancement of BCX9930 for Complement-Mediated Diseases: The oral factor D inhibitor, BCX9930, currently in Phase II clinical trials, targets a broad spectrum of complement-mediated diseases. This therapeutic area represents a large and diverse market with significant unmet medical needs across various indications. Successful progression through clinical development, particularly demonstrating efficacy and safety in Phase II and subsequent Phase III trials, could unlock a multi-billion dollar market opportunity. The oral administration route could offer a significant advantage over existing or developing injectable complement inhibitors, potentially positioning BCX9930 as a best-in-class therapy within a 5-7 year timeline if development is successful.
• Development of BCX9250 for Fibrodysplasia Ossificans Progressiva (FOP): BCX9250, an oral activin receptor-like kinase-2 (ALK-2) inhibitor in Phase I, targets fibrodysplasia ossificans progressiva (FOP), an ultra-rare and debilitating genetic disorder with no approved treatments that halt disease progression. The FOP market, while small in patient numbers, commands premium pricing due to the severity and rarity of the condition. Successful clinical development and regulatory approval of BCX9250 could establish BioCryst as a leader in this niche, providing a significant revenue stream. Given the early stage, this opportunity has a longer timeline, likely 7-10 years to potential commercialization, but offers high impact due to the lack of current effective therapies.
• Galidesivir for RNA Viruses: Galidesivir, an RNA dependent-RNA polymerase inhibitor in Phase I clinical trials, is being developed for the treatment of various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The market for antiviral therapies, especially for emerging and biodefense-related pathogens, is driven by public health needs and government procurement. Successful development and potential stockpiling by national health agencies could provide a stable, albeit potentially episodic, revenue stream. This opportunity is highly dependent on clinical success and global health priorities, with a timeline that could accelerate rapidly in the event of an outbreak or sustained public health concern, potentially within 5-10 years.
• Leveraging Strategic Collaborations and In-license Relationships: BioCryst's extensive network of collaborations with pharmaceutical companies like Torii Pharmaceutical, Seqirus UK, Shionogi, Green Cross, and Mundipharma, as well as governmental and academic institutions, provides a robust platform for growth. These partnerships facilitate global market access for existing products, share development costs and risks for pipeline assets, and enhance research capabilities. Expanding these relationships or forming new ones for specific regional markets or therapeutic areas can accelerate product commercialization, broaden geographical reach, and diversify revenue streams, contributing to sustained growth over the medium to long term (3-10 years).

What Opportunities Does BCRX Have?

• Expand ORLADEYO's market penetration globally and increase patient adoption in existing markets.
• Successful clinical development and regulatory approval of BCX9930 for various complement-mediated diseases, unlocking a large market.
• Advancement of BCX9250 for fibrodysplasia ossificans progressiva (FOP) to address an ultra-rare disease with high unmet need.
• Potential for Galidesivir to address global health threats from RNA viruses, leading to government contracts or stockpiling.

What Threats Does BCRX Face?

• Clinical trial failures or unexpected safety issues for pipeline candidates, leading to significant R&D write-offs.
• Intense competition from larger pharmaceutical companies and other biotechnology firms in targeted therapeutic areas.
• Regulatory hurdles and delays in obtaining approvals for new drugs, impacting commercialization timelines.
• Market acceptance and reimbursement challenges for new therapies, particularly in competitive or niche markets.
• Patent expirations or challenges to intellectual property protecting its key products.

What Are BCRX's Competitive Advantages?

• Proprietary Oral Small-Molecule Expertise: BioCryst specializes in developing novel, oral, small-molecule drugs, offering a differentiated approach in therapeutic areas often dominated by injectables, enhancing patient convenience and adherence.
• Targeted Rare Disease Focus: The company targets specific rare diseases like hereditary angioedema (HAE) and fibrodysplasia ossificans progressiva (FOP), where unmet medical needs are high and market entry barriers are significant due to specialized R&D and regulatory pathways.
• Intellectual Property Protection: Patents covering its approved products, such as ORLADEYO, and pipeline candidates provide exclusive rights, protecting against generic competition and allowing for market exclusivity.
• Strategic Global Collaborations: Extensive partnerships with international pharmaceutical companies and governmental bodies facilitate broader market access, shared development risks, and enhanced commercialization capabilities, strengthening its global footprint.
• Advanced Clinical Pipeline: A diverse pipeline of drug candidates in various stages of development, particularly BCX9930 for complement-mediated diseases, offers multiple future revenue opportunities and reduces reliance on a single product.

What Does BCRX Do?

BioCryst Pharmaceuticals, Inc., founded in 1986 and headquartered in Durham, North Carolina, is a biotechnology company dedicated to the discovery, development, and commercialization of novel, oral, small-molecule medicines. The company's strategic focus is on addressing rare and serious diseases where significant unmet medical needs persist. Over its history, BioCryst has evolved from a research-focused entity into a commercial-stage biotechnology firm with approved products and a robust development pipeline. The company's commercial portfolio includes peramivir injection, an intravenous neuraminidase inhibitor marketed under the names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. A cornerstone of BioCryst's current market position is ORLADEYO (berotralstat), an oral serine protease inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older. ORLADEYO represents a significant advancement in HAE management, offering a convenient oral option compared to traditional injectable therapies. Beyond its marketed products, BioCryst maintains an active and diverse pipeline of drug candidates. This includes BCX9930, an oral factor D inhibitor currently in Phase II clinical trials for various complement-mediated diseases, which represents a broad therapeutic area with high potential. Another key pipeline asset is BCX9250, an oral activin receptor-like kinase-2 (ALK-2) inhibitor, which is in Phase I clinical trials for the treatment of fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Additionally, Galidesivir, an RNA dependent-RNA polymerase inhibitor, is in Phase I clinical trials targeting a range of RNA viruses, such as Marburg, Yellow Fever, Ebola, and Zika, highlighting the company's commitment to addressing global health threats. BioCryst's operational strategy is significantly bolstered by a network of collaborations and in-license relationships. These partnerships include agreements with entities such as Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited for the commercialization and development of its products in various international markets. Furthermore, the company engages with governmental and academic institutions, including the National Institute of Allergy and Infectious Diseases, Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd., to advance its research and development initiatives. This collaborative approach enhances BioCryst's capabilities in drug discovery, clinical development, and global market access, solidifying its position within the competitive biotechnology landscape.

What Products and Services Does BCRX Offer?

• Discovers and develops novel, oral, small-molecule medicines for rare and serious diseases.
• Markets peramivir injection (RAPIVAB, RAPIACTA, PERAMIFLU) for acute uncomplicated influenza.
• Commercializes ORLADEYO, an oral serine protease inhibitor, for the prophylactic treatment of hereditary angioedema (HAE).
• Conducts Phase II clinical trials for BCX9930, an oral factor D inhibitor for complement-mediated diseases.
• Develops BCX9250, an oral ALK-2 inhibitor, in Phase I for fibrodysplasia ossificans progressiva (FOP).
• Advances Galidesivir, an RNA dependent-RNA polymerase inhibitor, in Phase I for various RNA viruses like Ebola and Zika.
• Engages in strategic collaborations and in-license relationships for drug development and commercialization globally.

How Does BCRX Make Money?

• Generates revenue primarily through the sales of its approved pharmaceutical products, notably ORLADEYO for hereditary angioedema and peramivir injection for influenza.
• Potentially earns milestone payments and royalties from its licensing agreements with various pharmaceutical partners for the commercialization of its products in specific territories.
• Invests a significant portion of its capital into research and development activities to discover and advance new drug candidates through clinical trials.
• Seeks to obtain regulatory approvals for its pipeline assets, which upon commercialization, would contribute to future product sales revenue.
• Leverages collaborations with governmental and academic institutions to support early-stage research and development, potentially reducing internal R&D costs and expanding scientific expertise.

What Industry Does BCRX Operate In?

BioCryst Pharmaceuticals operates within the dynamic and innovation-driven Biotechnology industry, a sub-sector of Healthcare. This industry is characterized by extensive research and development, lengthy clinical trials, and significant regulatory hurdles, all aimed at discovering and commercializing novel therapeutic solutions. BioCryst's focus on rare diseases and conditions like hereditary angioedema (HAE), complement-mediated diseases, and fibrodysplasia ossificans progressiva (FOP) positions it within a specialized niche. The broader biotechnology market is experiencing trends driven by advancements in genomics, personalized medicine, and a growing demand for targeted therapies for conditions with high unmet medical needs. Competition is intense, with numerous pharmaceutical and biotech companies vying for market share through innovative drug development. BioCryst differentiates itself through its expertise in oral, small-molecule medicines, aiming to provide more convenient and accessible treatment options. Its primary competitor in the broader rare disease space, as indicated by FMP peer data, includes companies like Spyre Therapeutics, Inc. (SYRE), which also focuses on novel therapeutic approaches, underscoring the competitive landscape for innovative drug platforms.

Who Are BCRX's Key Customers?

• Patients diagnosed with hereditary angioedema (HAE) who require prophylactic treatment.
• Healthcare providers, including physicians, specialists, and hospitals, who prescribe and administer the company's medicines.
• Patients suffering from acute uncomplicated influenza, for whom peramivir injection is indicated.
• Potentially, government agencies and public health organizations for antiviral therapies like Galidesivir, particularly in the context of biodefense or pandemic preparedness.
• Patients with complement-mediated diseases or fibrodysplasia ossificans progressiva, pending successful development and approval of pipeline candidates.

BioCryst Pharmaceuticals, Inc. Financial Trajectory

BioCryst Pharmaceuticals, Inc. (BCRX) reported $156.4M in revenue for Q1 2026, a decline of 61.5% compared to the prior quarter. The company recorded a net loss of $721.8M, with diluted EPS of $-2.98. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, BCRX averaged $-0.45 in diluted EPS.

Company Profile

BioCryst Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Durham, US. The company is led by CEO Charles K. Gayer. BCRX has traded publicly since 1994.

How BioCryst Pharmaceuticals, Inc. Is Valued

BioCryst Pharmaceuticals, Inc. carries a market capitalization of $2.11B, placing it in the mid-cap category. Relative to its peer group, BCRX's quantitative score of 12/100 is below the peer average of 78/100.

ROE 124%Key Financial Metrics

Return on equity for BioCryst Pharmaceuticals, Inc. stands at 123.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -98.5%, showing how much profit it generates from its asset base. Its free cash flow yield is 17.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.91 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -23.1%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 3/9Financial Health

BioCryst Pharmaceuticals, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -5.82 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project BioCryst Pharmaceuticals, Inc. revenue of about $671.0M for fiscal 2026, with EPS near $-2.61. The estimate reflects 6 contributing analysts.

Net buyingInsider Activity

Over the past six months, BioCryst Pharmaceuticals, Inc. insiders filed 15 SEC Form 4 transactions — 0 sales and 15 purchases. On net that is roughly 357K shares acquired (about $2.0M) — insiders putting money in tends to read as conviction.

BCRX Financials

BCRX Latest News

BCRX Analyst Consensus

BCRX MoonshotScore

Latest BioCryst Pharmaceuticals, Inc. Analysis

What Investors Ask About BioCryst Pharmaceuticals, Inc. (BCRX) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources